Aytu BioPharma

141 articles about Aytu BioPharma

• Aytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET

  2/12/2018

  Aytu BioScience today provided an overview of its business, including the Company's operational and financial results for its fiscal second quarter ended December 31, 2017.

• Aytu BioScience to Report Fiscal Second Quarter 2018 Results and Business Update

  2/1/2018

  The Company will review recent accomplishments and provide an overview of its business and growth strategy.

• Aytu BioScience Announces Appointment of David Green as CFO

  12/18/2017

  Mr. Green is a highly accomplished CFO, who brings an extensive array of financial, accounting, and operational experience to Aytu.

• Acerus Secures CDN$1.6M of New NATESTO Orders from Its U.S. Licensee Aytu Bioscience

  11/30/2017

  As per the terms of the License and Supply Agreement with Aytu, revenues associated with these orders will be recognized on delivery of the product to Aytu, with additional revenues recognized quarterly based on a percentage of net sales.

• Aytu BioScience Provides Update on the Continued Growth of Natesto in the U.S.

  11/28/2017

  Significant Natesto prescription growth continued through October 2017, with prescriptions increasing 17% from the previous month, reaching their highest levels to date.

• Aytu BioScience Provides Fiscal First Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET

  11/10/2017

  The Company will host a live conference call and webcast today at 4:30 p.m. ET. Conference call details are provided at the end of this press release.

• Aytu BioScience Receives Market Approval From the Australian Therapeutic Goods Administration for the MiOXSYS System for Male Infertility

  11/7/2017

  MiOXSYS has been approved by the TGA as an aid in the diagnostic assessment of semen quality for patients undergoing male infertility evaluation.

• Aytu BioScience to Report Fiscal First Quarter 2018 Results and Business Update

  11/2/2017

  Live Conference Call and Webcast Scheduled for November 9, 2017, at 4:30 p.m. ET

• Aytu BioScience Presents Clinical Findings for its MiOXSYS System at 73rd Annual Meeting of the ASRM

  11/1/2017

  Aytu BioScience today announced that it presented six posters demonstrating the clinical potential of MiOXSYS, the company's rapid in vitro diagnostic system for the qualitative measurement of static oxidation-reduction potential (sORP) in human semen, to be used as an aid in the diagnosis of infertility in males.

• Aytu BioScience Provides Quarterly Update on the Natesto U.S. Launch

  10/26/2017

  Aytu BioScience today provided an update on the ongoing launch of Natesto in the U.S.

• Aytu BioScience Announces Uplisting to The NASDAQ Capital Market

  10/18/2017

  Aytu BioScience today announced that its shares of common stock were approved for listing on The NASDAQ Capital Market.

• Aytu BioScience Announces International Distribution Agreement For Fiera In Japan

  10/3/2017

• Aytu BioScience Common Stock Resumes Trading Under Symbol 'AYTU' Today

  9/28/2017

• Aytu BioScience Provides Update On The Natesto U.S. Launch

  9/26/2017

• Aytu BioScience Provides Fiscal Fourth Quarter And Year-End 2017 Business Update

  9/1/2017

• Aytu BioScience Provides Fiscal Fourth Quarter And Year-End 2017 Business Update

  8/31/2017

• Aytu BioScience Announces Split-Adjusted Trading Of Its Common Stock

  8/29/2017

• Aytu BioScience Announces Reverse Split Of Its Common Stock

  8/28/2017

• Aytu BioScience To Provide Fiscal Fourth Quarter And Year-End 2017 Business Update

  8/24/2017

• Aytu BioScience Announces Closing Of $11.8 Million Private Placement

  8/16/2017